JP4944360B2 - 鉄ホメオスタシスの障害を治療するための医薬品を製造するためのヘプシジンの使用 - Google Patents

鉄ホメオスタシスの障害を治療するための医薬品を製造するためのヘプシジンの使用 Download PDF

Info

Publication number
JP4944360B2
JP4944360B2 JP2003501483A JP2003501483A JP4944360B2 JP 4944360 B2 JP4944360 B2 JP 4944360B2 JP 2003501483 A JP2003501483 A JP 2003501483A JP 2003501483 A JP2003501483 A JP 2003501483A JP 4944360 B2 JP4944360 B2 JP 4944360B2
Authority
JP
Japan
Prior art keywords
hepcidin
iron
mice
usf2
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2003501483A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004536077A5 (enExample
JP2004536077A (ja
Inventor
ニコラ，ガエル
ヴァウロン，ソフィー
カーン，アクセル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Santé et de la Recherche Médicale
Original Assignee
Institut National de la Santé et de la Recherche Médicale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27224392&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP4944360(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP01401537A external-priority patent/EP1262187A1/en
Application filed by Institut National de la Santé et de la Recherche Médicale filed Critical Institut National de la Santé et de la Recherche Médicale
Publication of JP2004536077A publication Critical patent/JP2004536077A/ja
Publication of JP2004536077A5 publication Critical patent/JP2004536077A5/ja
Application granted granted Critical
Publication of JP4944360B2 publication Critical patent/JP4944360B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/90—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving iron binding capacity of blood

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Emergency Medicine (AREA)
JP2003501483A 2001-05-25 2002-05-24 鉄ホメオスタシスの障害を治療するための医薬品を製造するためのヘプシジンの使用 Expired - Fee Related JP4944360B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP01401377.5 2001-05-25
EP01401377 2001-05-25
EP01401537.4 2001-06-14
EP01401537A EP1262187A1 (en) 2001-05-25 2001-06-14 Use of hepcidin for preparing a medicament for treating disorders of iron homeostasis
EP02290795 2002-03-29
EP02290795.0 2002-03-29
PCT/EP2002/006924 WO2002098444A2 (en) 2001-05-25 2002-05-24 Use of hepcidin for preparing a medicament for treating disorders of iron homeostasis

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2009006614A Division JP5717319B2 (ja) 2001-05-25 2009-01-15 鉄ホメオスタシスの障害を治療するための医薬品を製造するためのヘプシジンの使用
JP2011263858A Division JP2012111755A (ja) 2001-05-25 2011-12-01 鉄ホメオスタシスの調節剤としてのヘプシジンの使用

Publications (3)

Publication Number Publication Date
JP2004536077A JP2004536077A (ja) 2004-12-02
JP2004536077A5 JP2004536077A5 (enExample) 2012-01-26
JP4944360B2 true JP4944360B2 (ja) 2012-05-30

Family

ID=27224392

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2003501483A Expired - Fee Related JP4944360B2 (ja) 2001-05-25 2002-05-24 鉄ホメオスタシスの障害を治療するための医薬品を製造するためのヘプシジンの使用
JP2009006614A Expired - Lifetime JP5717319B2 (ja) 2001-05-25 2009-01-15 鉄ホメオスタシスの障害を治療するための医薬品を製造するためのヘプシジンの使用
JP2011263858A Pending JP2012111755A (ja) 2001-05-25 2011-12-01 鉄ホメオスタシスの調節剤としてのヘプシジンの使用
JP2014090333A Expired - Lifetime JP5847231B2 (ja) 2001-05-25 2014-04-24 鉄ホメオスタシスの調節剤としてのヘプシジンの使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2009006614A Expired - Lifetime JP5717319B2 (ja) 2001-05-25 2009-01-15 鉄ホメオスタシスの障害を治療するための医薬品を製造するためのヘプシジンの使用
JP2011263858A Pending JP2012111755A (ja) 2001-05-25 2011-12-01 鉄ホメオスタシスの調節剤としてのヘプシジンの使用
JP2014090333A Expired - Lifetime JP5847231B2 (ja) 2001-05-25 2014-04-24 鉄ホメオスタシスの調節剤としてのヘプシジンの使用

Country Status (12)

Country Link
US (4) US7169758B2 (enExample)
EP (2) EP2186524B1 (enExample)
JP (4) JP4944360B2 (enExample)
CN (2) CN101884780B (enExample)
AT (1) ATE427114T1 (enExample)
AU (1) AU2002321105A1 (enExample)
CA (1) CA2448382C (enExample)
CY (1) CY1120241T1 (enExample)
DE (1) DE60231804D1 (enExample)
ES (2) ES2326469T5 (enExample)
TR (1) TR201806761T4 (enExample)
WO (1) WO2002098444A2 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2186524B1 (en) † 2001-05-25 2018-02-21 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of hepcidin for preparing a medicament for treating disorders of iron homeostasis
EP1578254B1 (en) 2002-11-19 2013-03-06 DRG International, Inc. Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids and therapeutic uses therefor
US8017737B2 (en) 2002-11-19 2011-09-13 Hasan Kulaksiz Diagnostic methods for diseases by screening for hepcidin in human or animal tissues, blood or body fluids; monoclonal antibodies specific to human hepcidin and associated uses therefor
US7411048B2 (en) 2002-11-19 2008-08-12 Drg International, Inc. Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids
DE10349124A1 (de) 2003-10-22 2005-05-19 Roche Diagnostics Gmbh Differenzialdiagnostik mit Hepcidin
US20060063208A1 (en) 2004-08-02 2006-03-23 Woolf Clifford J DRG11-responsive (DRAGON) gene and uses thereof
KR100679100B1 (ko) * 2004-10-29 2007-02-06 엘지.필립스 엘시디 주식회사 수평 전계 인가형 액정 표시 패널 및 그 제조방법
EP2954903A1 (en) 2005-02-16 2015-12-16 The General Hospital Corporation Use of bmp antagonists to regulate hepcidin-mediated iron metabolism
WO2007120883A2 (en) * 2006-04-12 2007-10-25 Isis Pharmaceuticals, Inc. Compositions and their uses directed to hepcidin
EP2498096A1 (en) * 2006-07-21 2012-09-12 Amgen Inc. Method of detecting and/or measuring hepcidin in a sample
US20090209478A1 (en) 2006-09-21 2009-08-20 Tomoko Nakayama Compositions and methods for inhibiting expression of the hamp gene
US20110053268A1 (en) * 2006-10-17 2011-03-03 Naohisa Tomosugi Method for diagnosis of abnormal iron metabolism using active hepcidin as indicator
PE20130588A1 (es) * 2007-02-02 2013-05-21 Amgen Inc Hepcidina, antagonistas de la hepcidina y metodos de uso
WO2008124768A1 (en) 2007-04-09 2008-10-16 The General Hospital Corporation Hemojuvelin fusion proteins and uses thereof
US8187827B2 (en) 2007-05-31 2012-05-29 Naohisa Tomosugi Diagnostic methods for acute ischemic disease using activated hepcidin as an indicator
ATE553778T1 (de) 2007-10-02 2012-05-15 Inst Nat Sante Rech Med Für humanes hepcidin spezifische antikörper
US8530619B2 (en) 2007-10-26 2013-09-10 University Of Utah Research Foundation Identification of the hepcidin binding site on ferroportin
PE20091261A1 (es) * 2007-11-02 2009-08-17 Lilly Co Eli Anticuerpos anti-hepcidina
WO2009139822A1 (en) 2008-05-01 2009-11-19 Amgen Inc. Anti-hepcidin antibodies and methods of use
UA103032C2 (uk) * 2008-08-06 2013-09-10 Елі Ліллі Енд Компані Селективні антитіла проти гепсидину-25 та їх застосування
US20100068737A1 (en) * 2008-09-16 2010-03-18 University Of Tennessee Research Foundation Enzyme-linked Immunosorbent Assay (ELISA) for Canine Hepcidin
CA2742871C (en) 2008-11-13 2018-10-23 Herb Lin Methods and compositions for regulating iron homeostasis by modulation of bmp-6
US8999935B2 (en) * 2009-02-11 2015-04-07 New York University Treatment of osteoporosis in peri- and post-menopausal women with hepcidin
DE102009034150A1 (de) 2009-07-20 2011-01-27 Fresenius Medical Care Deutschland Gmbh Adsorbens zur Adsorption von Hepcidin
CN102574805A (zh) 2009-08-20 2012-07-11 维福（国际）股份公司 新型喹啉铁调素拮抗剂
AR077958A1 (es) 2009-08-27 2011-10-05 Vifor Int Ag Quinoxalinonas antagonistas de la hepcidina
AR077999A1 (es) 2009-09-02 2011-10-05 Vifor Int Ag Antagonistas de pirimidin y triazin-hepcidina
BR112012005119A2 (pt) 2009-09-07 2016-11-22 Vifor Int Ag novos antagonistas de hepcidina etanodiaminas
WO2011029832A1 (de) 2009-09-09 2011-03-17 Vifor (International) Ag Neue thiazol- und oxazol-hepcidin-antagonisten
US20120214803A1 (en) 2011-02-18 2012-08-23 Vifor (International) Ag Novel Sulfonaminoquinoline Hepcidin Antagonists
EP2723861A4 (en) 2011-06-21 2014-12-10 Alnylam Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR INHIBITING HEPCIDINE ANTIMICROBIAL PEPTIDE (HAMP) OR THE ASSOCIATED GENE EXPRESSION
WO2013002354A1 (ja) * 2011-06-29 2013-01-03 株式会社ダナフォーム 生体試料の前処理方法、ｒｎａの検出方法及び前処理キット
HK1200842A1 (en) 2011-11-18 2015-08-14 Albumedix Ltd Proteins with improved half-life and other properties
CA2904357C (en) 2013-03-15 2020-09-22 Intrinsic Lifesciences Llc Anti-hepcidin antibodies and uses thereof
US20160051556A1 (en) 2013-03-21 2016-02-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and Pharmaceutical Composition for use in the Treatment of Chronic Liver Diseases Associated with a Low Hepcidin Expression
CA2961917A1 (en) 2014-09-22 2016-03-31 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
US10098878B2 (en) 2014-10-10 2018-10-16 The Board Of Regents Of The University Of Texas System HIF-2α inhibitors for treating iron overload disorders
EP3399996A4 (en) * 2016-01-08 2019-10-16 La Jolla Pharmaceutical Company METHOD FOR THE ADMINISTRATION OF HEPCIDINE
WO2018165186A1 (en) * 2017-03-07 2018-09-13 Intrinsic Lifesciences Llc Assessment of chronic iron deficiency
US20190315821A1 (en) * 2018-02-23 2019-10-17 La Jolla Pharmaceutical Company Compositions comprising hepcidin and methods of use thereof
US12011489B2 (en) 2022-03-30 2024-06-18 Christopher Key Compositions and methods for treating inflammatory disease

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2766207B1 (fr) * 1997-07-11 2000-12-08 Rhone Poulenc Agrochimie Gene chimere codant pour la drosomycine, vecteur le contenant pour la transformation des cellules vegetales et plantes transformees obtenues resistantes aux maladies
FR2770853B1 (fr) * 1997-11-07 1999-12-31 Rhone Poulenc Agrochimie Gene codant pour la thanatine, vecteur le contenant et plantes transformees obtenues resistantes aux maladies
US20030009013A1 (en) * 1998-12-30 2003-01-09 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU3269399A (en) * 1999-03-22 2000-10-09 Universitat Zurich Transforming growth factor (tfg) beta superfamily antagonists
EP2186524B1 (en) 2001-05-25 2018-02-21 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of hepcidin for preparing a medicament for treating disorders of iron homeostasis
EP1578254B1 (en) † 2002-11-19 2013-03-06 DRG International, Inc. Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids and therapeutic uses therefor
US7411048B2 (en) * 2002-11-19 2008-08-12 Drg International, Inc. Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids
US8017737B2 (en) * 2002-11-19 2011-09-13 Hasan Kulaksiz Diagnostic methods for diseases by screening for hepcidin in human or animal tissues, blood or body fluids; monoclonal antibodies specific to human hepcidin and associated uses therefor
EP2954903A1 (en) * 2005-02-16 2015-12-16 The General Hospital Corporation Use of bmp antagonists to regulate hepcidin-mediated iron metabolism
CA2664066C (en) * 2006-09-16 2017-04-18 Soy Labs Llc Products and methods using soy peptides to lower total and ldl cholesterol levels
PE20130588A1 (es) † 2007-02-02 2013-05-21 Amgen Inc Hepcidina, antagonistas de la hepcidina y metodos de uso
ATE553778T1 (de) † 2007-10-02 2012-05-15 Inst Nat Sante Rech Med Für humanes hepcidin spezifische antikörper
WO2009097461A1 (en) 2008-01-29 2009-08-06 Neoguide Systems Inc. Apparatus and methods for automatically controlling an endoscope
WO2010065815A2 (en) † 2008-12-05 2010-06-10 The Regents Of The University Of California Mini-hepcidin peptides and methods of using thereof
BR112014013697A2 (pt) 2011-12-09 2020-11-03 The Regents Of The University Of California peptídeos mini-hepcidina modificados e métodos de uso dos mesmos
KR20170002414A (ko) 2014-04-07 2017-01-06 멀겐져 바이오텍, 아이엔씨. 헵시딘 모방 펩티드 및 그 용도
AU2015279571A1 (en) 2014-06-27 2017-02-02 Protagonist Therapeutics, Inc. Hepcidin and mini-hepcidin analogues and uses therof

Also Published As

Publication number Publication date
CA2448382C (en) 2013-02-19
CN101884780A (zh) 2010-11-17
US20050037971A1 (en) 2005-02-17
US20070124825A1 (en) 2007-05-31
ES2693050T3 (es) 2018-12-07
WO2002098444A3 (en) 2003-05-01
US9234903B2 (en) 2016-01-12
JP5847231B2 (ja) 2016-01-20
ES2326469T5 (es) 2018-05-28
US9782453B2 (en) 2017-10-10
CN1612746A (zh) 2005-05-04
EP1392345B2 (en) 2018-02-28
JP5717319B2 (ja) 2015-05-13
US20160166649A1 (en) 2016-06-16
US10004784B2 (en) 2018-06-26
ATE427114T1 (de) 2009-04-15
DE60231804D1 (de) 2009-05-14
JP2009143938A (ja) 2009-07-02
AU2002321105A1 (en) 2002-12-16
EP1392345B1 (en) 2009-04-01
US7169758B2 (en) 2007-01-30
JP2012111755A (ja) 2012-06-14
CN101884780B (zh) 2018-09-21
CY1120241T1 (el) 2019-07-10
CA2448382A1 (en) 2002-12-12
CN1612746B (zh) 2010-09-22
EP1392345A2 (en) 2004-03-03
US20170340710A1 (en) 2017-11-30
EP2186524B1 (en) 2018-02-21
JP2014210775A (ja) 2014-11-13
ES2326469T3 (es) 2009-10-13
WO2002098444A2 (en) 2002-12-12
EP2186524A1 (en) 2010-05-19
TR201806761T4 (en) 2018-06-21
JP2004536077A (ja) 2004-12-02

Similar Documents

Publication Publication Date Title
JP5847231B2 (ja) 鉄ホメオスタシスの調節剤としてのヘプシジンの使用
Jiang et al. Defining a link with autosomal-dominant polycystic kidney disease in mice with congenitally low expression of Pkd1
Courselaud et al. C/EBPα regulates hepatic transcription of hepcidin, an antimicrobial peptide and regulator of iron metabolism: cross-talk between C/EBP pathway and iron metabolism
Nishi et al. Cytoglobin, a novel member of the globin family, protects kidney fibroblasts against oxidative stress under ischemic conditions
Parry et al. Mouse embryogenesis requires the tissue factor extracellular domain but not the cytoplasmic domain
JP2007525952A (ja) Ｓ−ニトロソグルタチオンレダクターゼを調節するための組成物および方法
US20050031605A1 (en) Compositions and methods of treating diabetes
EP1262187A1 (en) Use of hepcidin for preparing a medicament for treating disorders of iron homeostasis
DE DK et al. DE LA RECHERCHE MEDICALE (INSERM)
Yesiltepe et al. Humanized TfR1 and transferrin gene-replacement rats for in vivo evaluation of BBB transport
US20070101445A1 (en) Transgenic mice carrying the HP-2 gene and uses as models for vascular diseases
JP4719862B2 (ja) カルシウム吸収促進剤
Ge Construction of adenoviruses and retroviruses of recombinant iron metabolism genes and their application in the studies on iron metabolism
CA2116012A1 (en) Transgenic non-human animal model for developing and testing therapies to treat sepsis
EP1832660A1 (en) Method of screening antiobesity drug

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050506

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050506

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080715

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081015

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20081022

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090115

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090414

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090811

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090910

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20091019

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20091106

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20111201

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120302

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 4944360

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150309

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees